Form 4: Director Kate Haviland Acquires Fulcrum Therapeutics Stock Options

Fulcrum Therapeutics Director Kate Haviland acquired stock options for 32,000 shares of common stock.

Summary

• Director Kate Haviland acquired 32,000 stock options for Fulcrum Therapeutics (FULC) common stock.
• The options have an exercise price of $3.66 and were granted on June 30, 2026.
• These options are scheduled to vest on the first anniversary of the grant date or immediately prior to the first annual meeting of stockholders after the grant date, provided continued service.
• The reporting person is Kate Haviland, with the filing made on July 2, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard grant of stock options to a director, which is a common compensation practice and does not inherently signal a significant positive or negative development.

Positives

• Director acquisition of stock options can signal confidence in the company's future prospects.
• The grant of options suggests a long-term incentive structure for management and directors.

Risks

• The value of the stock options is contingent on the future performance of Fulcrum Therapeutics' stock price.
• Vesting is subject to continued service, meaning the options could be forfeited if the director leaves the company before the vesting date.

Future Outlook

The stock options are exercisable at $3.66 and vest over time, indicating a long-term outlook for the company's stock performance.

Industry Context

StockSavvy.ai notes that the granting of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors as a means to align executive interests with shareholder value and incentivize long-term growth.

Stakeholder Impact

• Shareholders: The acquisition of options by a director may be viewed positively as a sign of commitment, but the actual impact depends on future stock performance.
• Employees: Standard compensation practice, unlikely to have a direct impact.
• Management: Aligns director incentives with long-term company performance.

Next Steps

• The stock options will vest according to the schedule outlined in the filing.
• The director may exercise the options upon vesting, subject to the terms of the plan.

Key Dates

Keywords

Fulcrum Therapeutics, FULC, Form 4, Stock Options, Director, Insider Trading, Securities, Executive Compensation